An observational study in Diabetic Nephropathies and Kidney Disease, Chronic, sponsored by Unity Health Toronto. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.
Sponsored by Unity Health Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Diabetic Nephropathies with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetic Nephropathies · Canada.
Among the 34 studies in Diabetic Nephropathies with a site in Canada, this one is one of 3 that started in 2019, is one of 3 observational ones, and was the 23rd registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →5 of the 34 studies in Diabetic Nephropathies with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18+
Alessandro Doria · Sites in Canada, United States
Ages 18–75
University of Washington · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 188 across 138 observational studies indexed under Diabetic Nephropathies.
Median enrollment 226 across the 31 interventional studies, 500 across the 3 observational. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 34 have an industry lead sponsor. The 10 most frequent:
Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Unity Health Toronto has 1 study filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetic Nephropathies with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05822609University of WashingtonTrial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Diabetic Nephropathies with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Despite decades of research, the pathogenesis of human diabetic kidney disease remains largely unclear. Our goal is to use archived human kidney biopsy tissue from patients with and with diabetic nephropathy to identify new molecules that drive and/or protect against disease progression. We will use RNA sequencing to identify transcriptomic changes that associate with histologic and functional outcomes.
RESEARCH OBJECTIVES A. To identify differences in transcription profiles obtained from residual kidney tissue which was obtained for clinical purposes.
B. To identify differences in transcription profile between patients whose loss of kidney function progresses rapidly (eGFR decline ≥4ml/min/year) and in whom it progresses more slowly (eGFR decline \<4ml/min/year).
C. To identify differences in transcription profile between predominantly glomerular and predominantly tubulointerstitial histopathological types .
D. To identify new pathogenetic pathways that may become targets for therapeutic intervention
METHODS The planned study centres on the use of archival biopsy material that is superfluous to what is or would be needed for clinical care (01/01/1995 to 31/05/2018 , n= approximately 400-500). Archived samples will be collected from St. Michael's Hospital and a number of collaborating centres, including but not limited to University of British Columbia, the University of Manitoba, and the University of Ottawa.
RNA will be extracted from the biopsy material using either the core that has been used for immunofluorescence microscopy and is stored at -80˚C, and/or the core that is formalin-fixed, embedded in paraffin wax and stored at room temperature. The RNA thereby extracted will be subjected to detailed interrogation by RNASeq to quantify the expression level of mRNAs (transcriptome) and compare differences, as indicated in the research objectives detailed above. The transcriptome will then be related to the clinical course (eGFR decline) and histopathological changes, in addition to examining potentially pathogenetically important and that are amenable to therapeutic intervention.
Histopathology will also be performed and classified according to established systems.
Clinical information that would be retrieved from patients' medical records are listed below.
Clinical data
Renal function measures and calculations. For example:
i. Serum creatinine, eGFR ii. Change in creatinine and eGFR iii. Urinary albumin:creatinine values and ratio (ACR) iv. Urine protein:creatinine values and ratio (PCR) v. Urinary protein excretion rate (UPEx) vi. Changes in ACR, PCR, UPEx
Each site will locally maintain a confidential Master Linking Log.
De-identified data will be entered into a secure REDCap database that is hosted by St. Michael's Hospital.
Inclusion Criteria (diabetic kidney disease cases):
Exclusion Criteria (diabetic kidney disease cases):
Inclusion Criteria (healthy controls):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
Other: RNA sequencing
Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
Other: RNA sequencing
Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
Also known as: Histology, Slope of eGFR decline
Interstitial fibrosis
Extent of interstitial fibrosis in kidney biopsy assessed using a semi-quantitative scale on light microscopy of biopsy sections
Time frame: Baseline biopsy
Glomerulosclerosis
Extent of glomerulosclerosis in kidney biopsy assessed using a semi-quantitative scale on light microscopy of biopsy sections
Time frame: Baseline biopsy
Renal function change
Slope of eGFR decline
Time frame: Baseline biopsy
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2019 (actual). Primary completion is estimated for Dec 2022, 41 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.